Research-based biopharmaceutical companies work in partnership with others to fight the malaria epidemic
WASHINGTON, April 25 /PRNewswire-USNewswire/ -- Despite being preventable and treatable, malaria continues to devastate communities in tropical regions throughout Latin America, Asia and Africa. According to the World Health Organization (WHO), the malaria epidemic causes debilitating disease in more than 500 million people worldwide and kills more than one million people each year - mostly infants, young children and pregnant women.
Global Health Progress, an initiative sponsored by the research-based biopharmaceutical companies of EFPIA, IFPMA, PhRMA and Rx&D, joins the global community in commemorating World Malaria Day on April 25. Research-based biopharmaceutical companies are committed to curbing the spread of malaria by working in partnership with governments, NGOs and others to provide education and treatment, and conduct research and development for new drugs and vaccines.
Research-based biopharmaceutical companies collaborate with initiatives such as Roll Back Malaria, the PATH Malaria Vaccine Initiative and the Medicines for Malaria Venture to accelerate the discovery of new medicines, vaccines, diagnostics and other health products to fight malaria. According to a study by the Malaria R&D Alliance, research-based biopharmaceutical and biotech companies fund 36 percent of all new R&D into products to combat malaria.
According to WHO, approximately 40 percent of the world's population are at risk for contracting malaria and, in Africa, malaria causes one in five childhood deaths. Around the world, research-based biopharmaceutical companies are actively engaged in combating malaria through partnerships to improve access to malaria treatments and interventions.
As of 2 November 2007, the R&D industry was conducting research on 24
new medicines and four candidate vaccines for malaria. This includes eight
|SOURCE Global Health Progress|
Copyright©2008 PR Newswire.
All rights reserved